Akari Therapeutics, Plc (ADR)
General ticker "AKTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.4M (TTM average)
Akari Therapeutics, Plc (ADR) follows the US Stock Market performance with the rate: 0.3%.
Estimated limits based on current volatility of 6.0%: low 7.46$, high 8.40$
Factors to consider:
- Total employees count: 12 as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operating losses, Capital shortage, Clinical trial failure, Regulatory and compliance, Manufacturing issues
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.98$, 28.17$]
- 2026-12-31 to 2027-12-31 estimated range: [3.91$, 14.37$]
Financial Metrics affecting the AKTX estimates:
- Negative: with PPE of -0.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Investing cash flow per share per price, % of 0 <= 2.40
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -14.91 <= 0
Short-term AKTX quotes
Long-term AKTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $16.81MM | $21.64MM | $17.27MM |
| Operating Income | $-16.81MM | $-21.64MM | $-17.27MM |
| Non-Operating Income | $6.80MM | $1.85MM | $-1.03MM |
| Interest Expense | $0.00MM | $0.24MM | $0.95MM |
| R&D Expense | $5.45MM | $6.98MM | $2.81MM |
| Income(Loss) | $-10.01MM | $-19.79MM | $-18.30MM |
| Taxes | $0.00MM | $0.00MM | $-1.00MM |
| Net Income(Loss)* | $-10.01MM | $-19.79MM | $-17.30MM |
| Stockholders Equity | $-0.23MM | $22.23MM | $28.33MM |
| Assets | $4.36MM | $50.56MM | $47.89MM |
| Operating Cash Flow | $-16.43MM | $-12.55MM | $-10.57MM |
| Investing Cash Flow | $0.00MM | $0.38MM | $0.00MM |
| Financing Cash Flow | $7.02MM | $10.99MM | $13.17MM |
| Earnings Per Share** | $-4,089.91 | $-3,313.97 | $-822.15 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.